Basel-based SunRegen Healthcare AG has entered into a binding Letter of Intent dated August 12, 2024 with Verisante Technology Inc, a company listed on the Canadian TSX Venture Exchange, to undertake a Reverse Takeover transaction with the resulting listed issuer carrying on the business of SunRegen.

总部位于巴塞尔的SunRegen Healthcare AG已于2024年8月12日与加拿大TSX风险交易所上市公司Verisante Technology Inc签订了一份具有约束力的意向书，以与经营SunRegen业务的上市发行人进行反向收购交易。

SunRegen focusses on the development of neurodegenerative related drugs. .

SunRegen专注于神经退行性疾病相关药物的开发。。

Both parties intend to negotiate and enter into a Definitive Share Exchange Agreement prior to September 30, 2024 and complete the Reverse Takeover transaction (RTO) with a proposed name change to SunRegen Pharmaceuticals Inc before December 31, 2024.SunRegen shareholders will own 90% of the outstanding common shares of the resulting issuer on a pre-money basis.

双方打算在2024年9月30日之前谈判并签订最终的换股协议，并在2024年12月31日之前完成反向收购交易（RTO），并将其更名为SunRegen Pharmaceuticals Inc。SunRegen股东将拥有最终发行人90%的已发行普通股。

The acquisition shares will have a deemed value of $0.80 per share for an aggregate deemed acquisition value of $31,635,363.Based in in Toronto, TSX Venture Exchange (TSXV) is a public venture marketplace for early-stage companies across a diverse range of sectors. As of May 2024 there were 1,632 companies listed on the TSXV with a market capitalization of CAD 82.2 billion (USD 59.9 bn).

收购股份的认定价值为每股0.80美元，总认定收购价值为31635363美元。多伦多证券交易所（TSXV）位于多伦多，是一家面向不同行业早期公司的公共风险投资市场。截至2024年5月，共有1632家公司在TSXV上市，市值822亿加元（599亿美元）。

TSVX is owned by the TMX Group which also owns the Toronto Stock Exchange..

TSVX由TMX集团拥有，TMX集团还拥有多伦多证券交易所。。

Capital raise in progressSunRegen’s pre-RTO capital raise is currently in progress. The next step is to complete the registered concurrent financing conducted by a sponsoring investment bank.The use of proceeds of the anticipated financing will be to advance the regulatory approval of SunRegen’s drug candidate SBC003 toward FDA Phase II by hiring a CRO to conduct CMC(Chemistry, Manufacturing, and Controls) and Safety studies for Retinitis Pigmentosa (“RP”)..

progressSunRegen的RTO前融资目前正在进行中。下一步是完成由赞助投资银行进行的注册并行融资。预期融资收益的使用将通过聘请CRO进行CMC（化学，制造和控制）和色素性视网膜炎（“RP”）的安全性研究，推动监管部门批准SunRegen的候选药物SBC003进入FDA第二阶段。。

RP is a hereditary family disease. Patients usually catch this disease at a young age, and it is generally manifested as apoptosis of peripheral retinal rod cells. The vast majority of RP patients cannot obtain effective treatment. Currently, there are approximately 2 million RP patients worldwide. Although RP is a rare disease, according to Data Bridge Market Research, the global RP market was worth US$11.57 billion and forecast to grow at a CAGR of 7.3% to reach US$20.33 billion by 2029.IND enabling stageTo date, approximately $6.3 million has been invested in the development of SBC003.

RP是一种遗传性家族疾病。患者通常在年轻时就感染这种疾病，通常表现为外周视网膜杆细胞凋亡。绝大多数RP患者无法获得有效治疗。目前，全世界约有200万RP患者。尽管RP是一种罕见疾病，但根据Data Bridge Market Research的数据，全球RP市场价值115.7亿美元，预计到2029年将以7.3%的复合年增长率增长至203.3亿美元。迄今为止，SBC003的开发已投资约630万美元。

Utilizing independent CROs, SunRegen has completed mice and monkey studies on the efficacy and partial safety of SBC003 with highly encouraging results and is now at the Investigational New Drug (IND) enabling stage of the FDA approval process. The next stage is to conduct CMC (Chemistry, Manufacturing, and Controls) and Safety tests in preparation for a Phase I & II human clinical study. SBC003 has also demonstrated prominent neuro-rescuing effects for indications including dry Age-Related Macular Degeneration (DAMD), Primary Optic Atrophy (POA) and Glaucoma Optic Atrophy (GOA)..

SunRegen利用独立的CRO完成了关于SBC003疗效和部分安全性的小鼠和猴子研究，结果令人鼓舞，目前正处于FDA批准过程的研究新药（IND）启用阶段。下一阶段是进行CMC（化学，制造和控制）和安全性测试，为I期和II期人体临床研究做好准备。SBC003还显示出显着的神经拯救作用，适用于干性年龄相关性黄斑变性（DAMD），原发性视神经萎缩（POA）和青光眼视神经萎缩（GOA）等适应症。。

(Press release / SK).

（新闻稿/SK）。

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送